Pfizer Inc. (NYSE:PFE) Receives Average Rating of "Hold" from Brokerages

Key Points

• Pfizer Inc. has been given a consensus rating of "Hold" by analysts, with one sell recommendation, eleven holds, four buys, and two strong buys among the eighteen brokerages covering the stock.
• The company's recent quarterly earnings beat analyst expectations, reporting $0.78 earnings per share against an estimate of $0.58, with revenue of $14.65 billion.
• Pfizer announced a quarterly dividend of $0.43, yielding approximately 7.0%, with a payout ratio of 91.49%.

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) have been assigned an average rating of "Hold" from the eighteen brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $28.1176.

Several research analysts have recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Berenberg Bank decreased their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Jefferies Financial Group boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st.

Pfizer Stock Down 3.8%

Pfizer stock traded down $0.95 during trading hours on Wednesday, hitting $23.91. The stock had a trading volume of 81,158,118 shares, compared to its average volume of 34,996,196. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $135.94 billion, a P/E ratio of 12.72, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer has a 12-month low of $20.92 and a 12-month high of $30.43. The stock's 50-day moving average price is $24.79 and its 200-day moving average price is $24.28.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Capital Advisory Group Advisory Services LLC raised its stake in shares of Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after purchasing an additional 388 shares during the last quarter. Citizens National Bank Trust Department raised its stake in shares of Pfizer by 0.9% in the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock worth $1,118,000 after purchasing an additional 395 shares during the last quarter. Peak Asset Management LLC raised its stake in shares of Pfizer by 1.4% in the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock worth $697,000 after purchasing an additional 402 shares during the last quarter. Able Wealth Management LLC raised its stake in shares of Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock worth $512,000 after purchasing an additional 413 shares during the last quarter. Finally, Trust Co of the South raised its stake in shares of Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after purchasing an additional 441 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.